These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Poirier J Ann N Y Acad Sci; 2000; 924():81-90. PubMed ID: 11193807 [TBL] [Abstract][Full Text] [Related]
6. [Expression of apolipoprotein E in Alzheimer's disease and its significance]. He SR; Liu DG; Wang S; Xia YJ Zhonghua Bing Li Xue Za Zhi; 2005 Sep; 34(9):556-60. PubMed ID: 16468304 [TBL] [Abstract][Full Text] [Related]
7. Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. Wood SJ; Chan W; Wetzel R Biochemistry; 1996 Sep; 35(38):12623-8. PubMed ID: 8823200 [TBL] [Abstract][Full Text] [Related]
8. Isoform-specific binding of human apolipoprotein E to the non-amyloid beta component of Alzheimer's disease amyloid. Olesen OF; Mikkelsen JD; Gerdes C; Jensen PH Brain Res Mol Brain Res; 1997 Feb; 44(1):105-12. PubMed ID: 9030704 [TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: implications for disease pathogenesis. Richey PL; Siedlak SL; Smith MA; Perry G Biochem Biophys Res Commun; 1995 Mar; 208(2):657-63. PubMed ID: 7695621 [TBL] [Abstract][Full Text] [Related]
10. Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide. Cottingham MG; Hollinshead MS; Vaux DJ Biochemistry; 2002 Nov; 41(46):13539-47. PubMed ID: 12427014 [TBL] [Abstract][Full Text] [Related]
11. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Strittmatter WJ; Weisgraber KH; Huang DY; Dong LM; Salvesen GS; Pericak-Vance M; Schmechel D; Saunders AM; Goldgaber D; Roses AD Proc Natl Acad Sci U S A; 1993 Sep; 90(17):8098-102. PubMed ID: 8367470 [TBL] [Abstract][Full Text] [Related]
12. The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation. Golabek AA; Soto C; Vogel T; Wisniewski T J Biol Chem; 1996 May; 271(18):10602-6. PubMed ID: 8631862 [TBL] [Abstract][Full Text] [Related]
13. Why lipids are important for Alzheimer disease? Hirsch-Reinshagen V; Burgess BL; Wellington CL Mol Cell Biochem; 2009 Jun; 326(1-2):121-9. PubMed ID: 19116777 [TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E and amyloidogenesis. Frangione B; Castaño EM; Wisniewski T; Ghiso J; Prelli F; Vidal R Ciba Found Symp; 1996; 199():132-41; discussion 141-5. PubMed ID: 8915608 [TBL] [Abstract][Full Text] [Related]
15. Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer's disease. Pillot T; Goethals M; Najib J; Labeur C; Lins L; Chambaz J; Brasseur R; Vandekerckhove J; Rosseneu M J Neurochem; 1999 Jan; 72(1):230-7. PubMed ID: 9886074 [TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. Han SH; Hulette C; Saunders AM; Einstein G; Pericak-Vance M; Strittmatter WJ; Roses AD; Schmechel DE Exp Neurol; 1994 Jul; 128(1):13-26. PubMed ID: 8070517 [TBL] [Abstract][Full Text] [Related]
17. Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. Näslund J; Thyberg J; Tjernberg LO; Wernstedt C; Karlström AR; Bogdanovic N; Gandy SE; Lannfelt L; Terenius L; Nordstedt C Neuron; 1995 Jul; 15(1):219-28. PubMed ID: 7619525 [TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein E polymorphism and Alzheimer's disease. Poirier J; Davignon J; Bouthillier D; Kogan S; Bertrand P; Gauthier S Lancet; 1993 Sep; 342(8873):697-9. PubMed ID: 8103819 [TBL] [Abstract][Full Text] [Related]
19. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Sadowski M; Pankiewicz J; Scholtzova H; Ripellino JA; Li Y; Schmidt SD; Mathews PM; Fryer JD; Holtzman DM; Sigurdsson EM; Wisniewski T Am J Pathol; 2004 Sep; 165(3):937-48. PubMed ID: 15331417 [TBL] [Abstract][Full Text] [Related]
20. Abeta20-29 peptide blocking apoE/Abeta interaction reduces full-length Abeta42/40 fibril formation and cytotoxicity in vitro. Hao J; Zhang W; Zhang P; Liu R; Liu L; Lei G; Su C; Miao J; Li Z Neuropeptides; 2010 Aug; 44(4):305-13. PubMed ID: 20363024 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]